Preparing for China · patient guide

Myelodysplastic syndrome care: questions to settle before you travel

Before travelling to China for myelodysplastic syndrome (MDS) care, settle one question first: what is the treating team actually being asked to decide? MDS covers a range of marrow disorders with different risk profiles and treatment goals, so a useful plan depends on a confirmed diagnosis, a documented risk assessment, current blood counts and a clear question about observation, transfusion support, disease-modifying therapy or transplant assessment. Ask the receiving hospital in writing what it can review, what it needs and what it can confirm before you book.

Go to the practical guidance ↓
AI illustration: Desk with a globe, clipboard, pen, books, a blue binder, a passport, and a potted plant near a window showing a traditional Asian building.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Start with the diagnosis and risk profile, not the destination

MDS is not one condition with one treatment. The World Health Organization classification and the International Consensus Classification describe subtypes of myeloid neoplasm, and the revised International Prognostic Scoring System (IPSS-R) combines marrow blast percentage, karyotype, haemoglobin, platelet count and absolute neutrophil count to place a patient in a risk group. Those details shape whether a clinician discusses monitoring, growth factors, transfusion, hypomethylating therapy or stem cell transplantation.

That matters for travel planning because a hospital cannot give a meaningful opinion on a vague label. If your records say only "MDS" without subtype, cytogenetics, blast count or a risk score, the first useful step is to establish what is already documented and what is missing. Ask your current haematologist which classification and prognostic system were applied and whether the marrow sample has been reviewed by a reference laboratory.

A records-based review in China can discuss the documented evidence, but it cannot replace a fresh marrow examination if the treating team considers one necessary. It also cannot confirm hospital acceptance or treatment availability in advance. Treat any preliminary reply as a starting point for questions, not a decision.

Decide what you want the China consultation to answer

Overseas patients contact hospitals for different reasons, and the reason changes what records and arrangements matter. One patient wants confirmation of the diagnosis and risk group. Another wants to discuss whether a hypomethylating agent, immunosuppressive approach or clinical trial is appropriate. A third is exploring allogeneic transplantation and needs to know whether a donor search and transplant assessment are realistic.

Write your question in one or two sentences before you send anything. For example: "Given this karyotype and blast count, is the current treatment plan appropriate, and what alternatives should be considered?" Or: "Is this patient a candidate for transplant assessment, and what additional testing would the centre require?" A precise question helps a haematology team route the enquiry and helps you judge whether the reply actually addresses your concern.

Be cautious about a reply that offers a treatment plan without the key documents. A responsible clinician will usually want the marrow report, cytogenetics, flow cytometry, blood count trends and a medication and transfusion history. If those are absent, ask what the opinion is based on and what remains uncertain.

Transfusion support and medicine continuity need written answers

Many people with MDS rely on red cell or platelet transfusions, and some take medicines that must not be interrupted abruptly. These are practical questions that should be settled with the receiving hospital before travel, not assumed from a general impression of Chinese hospitals.

Ask specifically whether the hospital can provide the transfusion support you may need, how blood products are arranged, what blood group and antibody records it requires, and what the treating team advises about timing around travel. Ask whether your current medicines are available, what documentation the hospital needs for them, and who will manage dose decisions. Prescribing and dispensing belong to licensed clinicians and the relevant pharmacy; a coordination service does not decide them.

If you are on a hypomethylating agent or another scheduled therapy, ask how the hospital handles continuation versus re-assessment, and what it would need to see before agreeing to either. Do not stop or change a medicine in preparation for travel without your prescribing clinician's instruction.

Transplant and trial questions are eligibility questions, not bookings

Allogeneic stem cell transplantation is a potential treatment for some patients with higher-risk MDS, but suitability depends on disease risk, age, general health, donor availability and the centre's own assessment. A review of records can start that conversation; it does not establish transplant eligibility, a donor match or access to a transplant slot.

The same boundary applies to clinical trials. A trial has its own eligibility criteria, and a hospital's interest in a case does not mean enrolment is possible. If a trial is part of your question, ask the centre which trials it is currently running for MDS, what the eligibility criteria require and whether a separate ethics and screening process applies. Do not treat a preliminary expression of interest as confirmed access.

For both transplant and trials, ask what the assessment pathway looks like, what tests would be repeated in China, and what the hospital can and cannot confirm remotely. Those answers determine whether travel is worth arranging now or later.

Assemble records that let a haematologist work

A useful MDS file is compact but specific. It should let a haematologist see the disease over time, not just at one moment. Start with the reports you already hold and ask the receiving team what else it needs rather than ordering tests yourself.

Include the bone marrow aspirate and trephine biopsy reports, cytogenetics and any molecular studies such as targeted myeloid panels, flow cytometry, and the full blood count trend with differentials. Add ferritin, erythropoietin and vitamin studies if done, transfusion records with dates and products, and a list of current and previous MDS-directed medicines with dates and responses. Include the latest clinic letters and a short summary of your main question.

Ask the hospital how it wants records sent, in what language, and whether translated summaries are acceptable alongside originals. Keep a copy with you. Do not send passport numbers, payment details or a complete archive through an initial enquiry form; share clinical documents only through the channel the provider confirms.

Agree the scope and the next step before committing

Once the clinical question is clear, agree what the China side will actually provide. A specialist appointment, a records-based opinion and a multidisciplinary review are different services with different limits. Ask which one fits your question, who will give the opinion, what records will be reviewed and what the written output will contain.

Costs should be discussed in the same conversation. Hospital consultation, tests, treatment, medicines and rooms are paid to the hospital or relevant provider, while coordination fees are separate. Ask for the actual written quote and what it covers rather than relying on a general range. If a figure is not confirmed for your situation, ask for an individual estimate based on your records.

ChinaSpecialistCare's team can check the available diagnosis and records, identify missing information and suggest the relevant next step through a free initial case review. That review is not a diagnosis and does not promise acceptance. A proxy consultation with a hospital specialist is optional, not a prerequisite for every appointment. The hospital and its clinicians decide suitability, treatment and acceptance.

A practical next step is to write your one-sentence question, gather the reports listed above and send a brief summary through the enquiry form, email or WhatsApp. Ask the team to confirm what the receiving hospital needs and what it can address before you make any travel commitment.

Related treatment reference

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. Myelodysplastic Syndromes Treatment - NCI

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.